Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck F Rahaghi

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Therapeutic Advances in Chronic Disease|August 19, 2021
Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what's down the road?Franck F Rahaghi
Respiratory Research|June 1, 2017
Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidenceFranck F Rahaghi, Marc Miravitlles
Respiratory Medicine|March 8, 2023
The role of riociguat in combination therapies for pulmonary arterial hypertensionFranck F Rahaghi, Maria Giovanna Trivieri, Sandeep Sahay
Cureus|March 19, 2024
Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging TherapyVanessa C Perez, Veronica Williams, Franck F Rahaghi
European Respiratory Review : an Official Journal of the European Respiratory Society|March 22, 2020
Clinical phenotyping: role in treatment decisions in sarcoidosisRobert P Baughman, Mary Beth Scholand, Franck F Rahaghi
BMJ Case Reports|October 11, 2012
Unusual cause of shortness of breath after surgery for thoracic outlet syndromeJonathan Ryan Schroeder, Anjan Kumar, Edward Savage, et al.
Chest|September 11, 2024
A 76-Year-Old-Man With Dyspnea and Abnormal Oximetry RunVeronica Williams, Franck F Rahaghi, Ian R Drexler, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 10, 2020
Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency RegistryFranck F Rahaghi, Richard Monk, Viswanathan Ramakrishnan, et al.
Respiratory Medicine|July 23, 2017
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionNicholas S Hill, Franck F Rahaghi, Namita Sood, et al.
Cardiovascular Drugs and Therapy|May 20, 2020
Inpatient Initiation of Oral Treprostinil in an Academic Medical SystemBenjamin Hohlfelder, Adriano R Tonelli, Gustavo A Heresi, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Chronic Disease|August 19, 2021
Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what's down the road?Franck F Rahaghi
Respiratory Research|June 1, 2017
Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidenceFranck F Rahaghi, Marc Miravitlles
Respiratory Medicine|March 8, 2023
The role of riociguat in combination therapies for pulmonary arterial hypertensionFranck F Rahaghi, Maria Giovanna Trivieri, Sandeep Sahay
Cureus|March 19, 2024
Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging TherapyVanessa C Perez, Veronica Williams, Franck F Rahaghi
European Respiratory Review : an Official Journal of the European Respiratory Society|March 22, 2020
Clinical phenotyping: role in treatment decisions in sarcoidosisRobert P Baughman, Mary Beth Scholand, Franck F Rahaghi
BMJ Case Reports|October 11, 2012
Unusual cause of shortness of breath after surgery for thoracic outlet syndromeJonathan Ryan Schroeder, Anjan Kumar, Edward Savage, et al.
Chest|September 11, 2024
A 76-Year-Old-Man With Dyspnea and Abnormal Oximetry RunVeronica Williams, Franck F Rahaghi, Ian R Drexler, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 10, 2020
Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency RegistryFranck F Rahaghi, Richard Monk, Viswanathan Ramakrishnan, et al.
Respiratory Medicine|July 23, 2017
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionNicholas S Hill, Franck F Rahaghi, Namita Sood, et al.
Cardiovascular Drugs and Therapy|May 20, 2020
Inpatient Initiation of Oral Treprostinil in an Academic Medical SystemBenjamin Hohlfelder, Adriano R Tonelli, Gustavo A Heresi, et al.
Pageof 3